| Name | Title | Contact Details |
|---|---|---|
Ryan Beal |
Chief Operating Officer | Profile |
Farzin Khaghani |
Senior Vice President of Information Technology | Profile |
Steve Varga |
Chief Technology Officer | Profile |
eSight empowers the low vision community and advocates to #SeeNewPossibilities for people with macular degeneration, diabetic retinopathy, and 50+ other conditions that cause vision loss. Founded by electrical engineer, Conrad Lewis, who wanted to help his two legally blind sisters see, eSight has since grown to become the leading sight enhancement platform led by an executive team with the vision to do more. After seven years of research and development, the first eSight Eyewear prototype was released in 2013. Since then, the vision-enhancing electronic technology has changed the lives of thousands of people living with visual impairments and legal blindness by allowing them to retain their independence and achieve greater visual acuity at home, school, work, and play. Soon after the release of eSight 3, Time Magazine named eSight in its list of “The 25 Best Inventions in 2017” and Buzzfeed featured the device on its roster of “6 Inventions Changing British People`s Lives In 2017”. Following eSight 3, the team continued to develop its technology and, in 2020, launched its latest model — eSight 4. It was thoughtfully crafted to be wireless and hands-free allowing users to retain their mobility as well as be lightweight and streamlined for all-day comfort. The eSight 4 was later recognized as the “Best Wearable/Healthcare Hardware/Software of 2021” by the Tech Ascension Awards, which honors companies that possess the most innovative technology in their respective industry.
Prudent Choice is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stormin Norman'S is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage its proprietary biomaterial and stent technologies to improve the treatment of coronary artery disease. Guided by an executive management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA’s initial focus is the development of a drug-eluting bioresorbable coronary scaffold to advance the treatment of cardiovascular disease, the leading cause of death worldwide.
Amrex-Zetron is a Carson, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.